

NOCTURNAL SCRATCH



Digital Measures Development

[DiMe](#) is a global non-profit that convenes organizations across the healthcare industry in a pre-collaborative consortia to tackle the toughest digital medicine challenges, develop clinical-quality resources on a tech timeline, and deliver these actionable resources to the field via open-source channels and educational programs. The [Nocturnal Scratch Digital Measures Development](#) project brought stakeholders together to produce resources that aim to advance the use of nocturnal scratch in the treatment of atopic dermatitis (AD).

The Patient Matters in the End(point)

By Pip Griffiths, Diana Rofail, Rea Lehner & Vera Mastey

- » Griffiths, et al. discuss how digital health technologies (DHTs), such as apps, sensors, and wearable devices, are increasingly used in clinical trials and result in various endpoints which may not be meaningful to the patient.
- » The authors speak to the importance of pre-competitive collaborations to develop patient-centered endpoints, using [DiMe's Nocturnal Scratch](#) project as an example of bringing stakeholders together to develop measures that matter.

“Lack of standardization could hinder the ability to compare results across trials. Pre-competitive collaboration that bring together pharmaceutical companies and other stakeholders, such as that initiated by DiMe, is crucial. This pre-competitive work... defines digital endpoints that are patient relevant, while making the research and resulting device specifications available to the broad community [and comparable across studies].”

— Griffiths, et al.

[Read the full article here](#)